Patient Derived Tumor Xenograft (PDX) Models for Breast Cancer

XenTechs’ flagship panel of patient derived tumor xenograft (PDX) models for breast cancer has been developed over the last 10 years. XenTech is the only company in the world to have such an extensive collection of PDX models.

The collection of breast cancer PDX models are composed of a majority of triple negative breast tumors and also contains Her2 amplified and oestrogen receptor positive tumor models.

PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.

Our PDX models are extensively characterized and are associated to molecular data including gene expression and copy number data.

Our studies have shown the clinical relevance of such models and their usefulness as a tool for predictive evaluation of the clinical efficacy of therapeutic agents.

For more information or to discuss patient derived tumor xenograft (PDX) models for breast cancer please contact us directly.